{
    "ticker": "ENTX",
    "name": "Entera Bio Ltd.",
    "description": "Entera Bio Ltd. is a biotechnology company focused on the development of innovative oral drug delivery systems for biologics. Founded in 2015 and headquartered in Jerusalem, Israel, Entera aims to revolutionize the administration of large-molecule therapeutics, which traditionally require injections or infusions. The company's proprietary technology platform is designed to enable the oral delivery of peptides and proteins, thereby enhancing patient compliance and expanding access to essential therapies. Entera's lead product candidate, EB613, is an oral formulation of parathyroid hormone (PTH) intended for the treatment of osteoporosis. With a robust pipeline of oral biologics, Entera is positioned to address significant unmet medical needs in various therapeutic areas, including metabolic bone diseases and diabetes. The company employs a multidisciplinary approach, combining its expertise in drug formulation, pharmacology, and clinical development to bring innovative therapies to market. Entera Bio is committed to improving the quality of life for patients by making complex biologic treatments more accessible and manageable, ultimately contributing to the advancement of personalized medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Jerusalem, Israel",
    "founded": "2015",
    "website": "https://www.enterabio.com",
    "ceo": "Dov Goldstein",
    "social_media": {
        "twitter": "https://twitter.com/EnteraBio",
        "linkedin": "https://www.linkedin.com/company/enterabio/"
    },
    "investor_relations": "https://ir.enterabio.com",
    "key_executives": [
        {
            "name": "Dov Goldstein",
            "position": "CEO"
        },
        {
            "name": "Michael L. P. Duffy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oral Biologics",
            "products": [
                "EB613 (oral PTH for osteoporosis)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Entera Bio Ltd. | Innovating Oral Drug Delivery",
        "meta_description": "Entera Bio Ltd. is at the forefront of developing oral delivery systems for biologics, enhancing patient compliance and access to therapies. Explore our innovative pipeline.",
        "keywords": [
            "Entera Bio",
            "Biotechnology",
            "Oral Drug Delivery",
            "Biologics",
            "Osteoporosis",
            "PTH"
        ]
    },
    "faq": [
        {
            "question": "What does Entera Bio specialize in?",
            "answer": "Entera Bio specializes in the development of oral drug delivery systems for biologics."
        },
        {
            "question": "Who is the CEO of Entera Bio?",
            "answer": "Dov Goldstein is the CEO of Entera Bio Ltd."
        },
        {
            "question": "Where is Entera Bio headquartered?",
            "answer": "Entera Bio is headquartered in Jerusalem, Israel."
        },
        {
            "question": "What is Entera Bio's lead product candidate?",
            "answer": "Entera Bio's lead product candidate is EB613, an oral formulation of parathyroid hormone for osteoporosis."
        },
        {
            "question": "When was Entera Bio founded?",
            "answer": "Entera Bio was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX",
        "SNY"
    ],
    "related_stocks": [
        "AAPL",
        "PFE",
        "JNJ",
        "MRNA"
    ]
}